集团累计实现汽车售后服务110.21万台次，实现售后服务收入约31.95亿元。 智通财经APP讯，正通汽车(01728)发布截至2024年12月31日止年度业绩，该集团期内取得收益207.47亿 元(人民币，下同)，同比减少14.03%;公司普通股股东应占亏损17.09亿元，同比扩大91.75%;每股基本亏 损56分。 截至2024年12月31日止年度，集团实现新车销售合共55054台，其中中高端品牌汽车销售46756台。新能 源新车型销量约5759台，约占本年度总销量的10.5%，台数和占比均较去年同期有进一步提升。 随着行业变革趋势逐步明晰，集团果断汰换弱势品牌。截至2024年12月31日止，集团在全国15个省、直 辖市的36个城市拥有93家运营网点，同时还有已获授权及筹建的经销店网点5家，分别来自1家豪华品牌 和4家新能源自主品牌，包括1家路虎4S店、1家AITO问界4S店、2家奇瑞iCAR 4S店以及1家捷途4S店。 2024年，集团荣登"2024中国汽车经销商集团百强排行榜"18名，较2023年提升4位。此外，集团成功入 围"2024中国汽车百强经销商集团 — 新能源分榜单"，并位列"2024中国汽 ...

Group 1 - The core business of the company is one-stop payment services, with a total payment transaction volume (GPV) of 2.34 trillion RMB in 2024, generating revenue of 2.686 billion RMB [1] - The overall gross margin improved from 18.7% in 2023 to 23.6% in 2024, while the profit for the period reached 73 million RMB, representing an increase of over six times compared to the previous year [1] - The company has seen significant growth in its overseas business, with transaction volume exceeding 1.1 billion RMB, marking a nearly fivefold year-on-year increase [1] Group 2 - The company has established an AI Lab since 2017, which began deploying and applying artificial intelligence in 2023, leading to a reduction in sales, administrative, and R&D expenses by 11.0%, 10.8%, and 10.5% respectively in 2024 [1] - The company launched the first local AI Agent solution in Southeast Asia, enhancing merchant services through AI technology, which significantly improved user experience and order conversion rates in restaurants [2] - The company's in-store e-commerce business is nearing breakeven, with a consensus on the potential for large-scale development while maintaining stable and healthy growth [2]

智通财经APP讯，四环医药(00460)公布2024年业绩，总收益约为人民币19.01亿元(单位下同)，同比上升 约2.2%。毛利约为12.42亿元，整体研究及开发开支约为4.74亿元，同比下降18.0%。年内经营活动的现 金流量流入净额约为2.44亿元。 其中，来自医美业务的销售收益约为7.44亿元，同比上升约65.4%，主要由于年内产品获得市场的高度 认可，从而推动医美销售收入大幅增长，叠加新产品销售带来的新增收入。 来自创新药及其他药品的收益约为5760万元，同比上升约388.1%。主要由于轩竹生物自研的一类新药 安奈拉唑钠于 2023年下半年获批上市并开始产生收入。以上销售收益的变动趋势符合国内当前的"创新 驱动，腾笼换鸟"的行业政策趋势。 虽然在集采降价等行业政策动态调整的影响下，该集团的仿制药业务的经营性指标呈现阶段性调整态 势，但也正是在市场变革创新的背景下，该集团在以"创新驱动+资源整合"为核心下实现多项业务突 破，包括：医美平台通过独家代理射频治疗仪SylfirmX获批上市及续签肉毒毒素乐提葆®独家代理权， 产品优势持续巩固。旗下创新药平台惠升生物制药股份有限公司、轩竹生物等子公司全年推动十 ...

Core Insights - The company reported a significant increase in revenue and profit for the fiscal year 2024, with total revenue reaching 3.087 billion RMB and net profit growing over six times to 73 million RMB compared to the previous year [1] - The company's core business, one-stop payment services, achieved a gross payment volume (GPV) of 2.34 trillion RMB, with revenue from this segment amounting to 2.686 billion RMB [1] - The company has expanded its overseas business significantly, with transaction volume exceeding 1.1 billion RMB, marking a nearly fivefold increase year-on-year [1] Financial Performance - Total revenue for 2024 was 3.087 billion RMB, with a gross margin improvement from 18.7% in 2023 to 23.6% in 2024 [1] - Net profit reached 73 million RMB, representing a growth of over 600% compared to the previous year [1] - The company's value-added services contributed 13.0% to total revenue, up from 11.8% in 2023, with gross margin for these services also improving from 18.7% to 23.6% [1] Business Expansion - The company partnered with 6,000 SaaS partners, a 32% increase year-on-year, and collaborated with nearly 160 acquiring banks [2] - The company achieved record-high business volume in precision marketing, with revenue from merchant solutions reaching 340 million RMB, a year-on-year increase of approximately 87.2% [2] - The company is focusing on high-quality, profitable clients in its local e-commerce services, adding new brands such as InterContinental Hotels and Joy City [2] International Growth - The company has established partnerships with major global payment networks like Visa, Mastercard, and UnionPay, enhancing its international payment acceptance capabilities [3] - The company has expanded its overseas operations into markets like Japan, Singapore, and Hong Kong, helping local merchants in sectors such as dining and tourism to globalize [3] - The company is also collaborating with its invested company, Fushi Technology, to provide a one-stop digital platform for international brands in Southeast Asia [4] Strategic Focus - The company aims to leverage artificial intelligence to enhance operational efficiency and product competitiveness [4] - The company is prioritizing localized operations in its global expansion strategy, responding to local market demands while utilizing its domestic operational experience [4] - The company plans to deepen the commercialization of a broader product matrix to solidify its position as a leading cross-regional one-stop payment and business empowerment technology platform [4]

Financial Performance - The company reported a net interest income of RMB 148.373 billion, remaining flat year-on-year [1] - Total revenue reached RMB 752.87 billion, an increase of 10.58% year-on-year [1] - Profit attributable to ordinary shareholders was RMB 58.202 billion, up 1.06% year-on-year, with basic earnings per share at RMB 2 and a proposed final dividend of RMB 0.36 per share [1] Financial Strategy - The company is focusing on strengthening its financial core, with over 90% of its assets in financial services, contributing 80% of its profits [2] - The implementation of the "strong core" initiative aims to enhance core functions and competitiveness across banking, securities, trust, insurance, and financial leasing [2] - Financial subsidiaries performed well, with net profit attributable to ordinary shareholders increasing by 4.3% to RMB 52.649 billion [2] Industrial Development - The company is advancing its industrial strategy through the "Star Chain" initiative, which aims to revitalize traditional industries and explore new growth areas [3] - The industrial sector's net profit attributable to ordinary shareholders reached RMB 16.352 billion, supported by various projects and collaborations [3] - The company is enhancing its competitive edge in agriculture and construction through strategic investments and partnerships [3] Technological Innovation - The company is increasing its investment in technological innovation, launching the "Rock" initiative to develop key laboratories and innovation platforms [4] - Significant research achievements have been made in advanced manufacturing, materials, and biotechnology [4] - The company is promoting the "AI+" initiative to leverage its data advantages and drive technology from experimental stages to market applications [4] International Expansion - The company has established a strong international presence, operating in approximately 160 countries and regions [5] - In 2024, the company saw a 3.2-fold increase in new overseas contracts and an 80% increase in new effective orders [5] - The company aims to enhance its role as a bridge for international trade and cooperation, hosting various global events to promote engagement [5]

智通财经APP讯，石四药集团(02005)发布截至2024年12月31日止年度业绩，集团收益57.73亿港元，同 比减少10.67%;股东应占溢利10.61亿港元，同比减少19.53%;每股基本盈利0.3582港元;拟派末期息每股 0.095港元。 大输液和安瓿水针产品业务保持稳定。2024年，集团输液整体累计实现销售量 20.36亿瓶(袋)，同比增 长6.7%，销售额37.35亿港元，同比减少7.6%，主要原因是受政策性和市场性叠加因素影响，基础输液 存量市场需求乏力、价格下滑，增长不及预期。尽管如此，2024年集团部分治疗性输液产品仍实现增 长，其中，腹膜透析液销量达855万袋，同比增长81%;盐酸莫西沙星氯化钠注射液销售量约1,798万袋， 同比增长约5%。年内，安瓿水针产品累计实现销售量3.13亿支，同比增长1.3%。其中，葡萄糖注射液 销售3,240万支，同比增长128%;异丙托溴铵销售1,214万支，同比增长163%;多索茶硷销售3,168万支，同 比增长57%。 口服制剂业务板块产销规模进一步提升。集团积极采取调整市场布局、强化专业化推广等手段，加强与 百强连锁等医药商业合作，推动商业连锁加快终 ...

智通财经APP讯，都市丽人(02298)发布截至2024年12月31日止年度业绩，收入30.1亿元(人民币，下 同)，同比增加9.18%;股东应占溢利1.26亿元，同比增加196.96%;每股基本盈利5.8分;拟派发末期股息每 股0.5港仙。 线下街铺渠道仍然是都市丽人的主要优势渠道。2024年，在复杂的市场环境下，集团的店铺实现了逆势 净增长，进一步巩固了在线下渠道的优势。 此外，集团通过"纯棉居物"品牌实现了在购物中心渠道的突破。纯棉居物定位于中高端市场，致力于为 消费者提供"纯棉、健康、舒适"的产品，打造一站式的家庭购物体验，形成与主品牌都市丽人的差异化 定位。凭借精致的产品和良好的购物体验，纯棉居物获得了消费者的广泛认可，2024年业绩较2023年同 比增长约50%。同时，凭借优异的业绩和盈利能力，纯棉居物赢得了众多加盟客户的青睐，开店意愿积 极。预计到2025年，纯棉居物有望实现店铺数量和业绩的翻倍增长，成为集团业绩增长的强劲动力。 于2024年，与截至2023年12月31日止年度相比，集团的毛利率维持稳定于约45.7%(2023年：47.5%)，其 中与截至2023年12月31日止年度相比，贴身衣 ...

Group 1 - The company reported a revenue of RMB 5.012 billion for the year ending December 31, 2024, representing a year-on-year growth of 47.9% [1] - Shareholders' profit attributable to the company was RMB 812 million, marking a turnaround from loss to profit [1] - The basic earnings per share were RMB 1.71, and the company proposed a final dividend of HKD 0.4 per share [1] Group 2 - The company's business and personnel structure became stable in 2024, with successful launches of self-developed games in multiple global markets [2] - New self-developed games, including "GoGo Muffin," "Sword of Convallaria," and "Heartopia," contributed to a 64.2% year-on-year increase in gaming business revenue [2] - The average monthly active users (MAU) of the TapTap China app grew by 23.0% year-on-year, reaching 44 million [2] - The collaboration between "Heartopia" and TapTap significantly increased new user acquisition and brand recognition for TapTap [2] - The company completed the filing for its generative AI service TapSight and integrated AI Q&A and DeepSeek search functionalities into TapTap [2] - The company is committed to incorporating AI and machine learning tools into daily operations and exploring new business development directions [2] - The long-term vision of the company is to continuously provide high-quality games for global players and support developers in creating and distributing games more conveniently [2]

智通财经APP讯，第一太平(00142)公布2024年业绩，营业额同比减少4.3%至100.572亿美，母公司拥有 人应占溢利同比增加19.8%至6.003亿美元，每股基本盈利14.15美仙，建议派发末期分派每股普通股 13.50港仙。 呈报溢利增长反映经常性溢利上升，与一项投资的减值拨备下降以及撇减资产相关的非经常性亏损下 降，部份被非现金汇兑亏损所抵消，其大部分与PT Indofood CBP Sukses Makmur Tbk(ICBP)以美元计值 的相关债券因印尼盾兑美元的收市汇率贬值5%有关，而2023年相关债券则取得汇兑收益。 经常性溢利由6.038亿美元上升11%至6.725亿美元，反映来自Indofood、MPIC及PLDT的溢利贡献上升， 部份因混合非燃料利润率下降及所得税开支上升令来自PLP的溢利贡献减少，来自Philex的溢利贡献因 现金营运成本增加而减少，以及总公司的利息开支净额上升所抵消。 公告称，营业额减少反映PLP收入下降，原因为电价回稳令平均售价下降，部份被Maynilad Water Services,Inc.(Maynilad)的收费用水量及实际水费增加，以及Metro P ...

Core Viewpoint - The company is showcasing its innovative drug development progress at the AACR annual meeting, emphasizing the importance of reliable clinical results for intrinsic value in the growing innovative drug sector [1][2]. Group 1: Clinical Research and Development - The company will present four new preclinical research results at the AACR conference, including the EGFR Exon20ins inhibitor ABSK112, PRMT5*MTA inhibitor ABSK131, and KRAS inhibitor [1]. - ABSK112 has demonstrated superior brain penetration, selectivity against wild-type EGFR, and a broader mutation coverage in preclinical studies, indicating its potential as a next-generation drug for non-small cell lung cancer (NSCLC) [2][3]. - ABSK131 targets the PRMT5 gene, which is associated with synthetic lethality in tumors lacking the MTAP gene, showing promise as a novel cancer treatment strategy [3]. Group 2: Financial Performance - In 2024, the company achieved approximately 504 million yuan in revenue, a significant year-on-year increase of 2544%, successfully turning a profit [1]. - The strong revenue growth and expected cash flow support the company's innovative research and development efforts, with 451 million yuan allocated for R&D during the reporting period [1]. Group 3: Market Position and Future Prospects - The company has established a competitive pipeline of 15 candidate drugs focusing on precision oncology and immunotherapy, with several candidates showing "best-in-class" or "first-in-class" potential [3]. - The stock price reached a peak of 8.98 HKD on March 28, marking the highest level since the second half of 2022, indicating the market's recognition of the company's intrinsic value [4].